X4 Pharmaceuticals (XFOR) Price to Sales (2020 - 2026)

X4 Pharmaceuticals (XFOR) has reported Price to Sales for 4 consecutive years, with 67.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 774.09% year-over-year to 67.0; the trailing twelve-month figure through Jun 2026 stood at 37.23 (up 7968.45% YoY), and the FY2025 full-year result was 4.82, down 90.18% from the prior year.
• Price to Sales slipped to 67.0 in Q2 2026 per XFOR's latest filing, from 192.6 in the prior quarter.
• Across five years, Price to Sales topped out at 6194.79 in Q2 2024 and bottomed at 1.43 in Q1 2025.
• Historically, Price to Sales has averaged 766.9 across 3 years, with a median of 83.85 in 2025.
• The sharpest annual moves came in 2025 and 2026: Price to Sales sank 99.88% in 2025, then jumped 13414.84% in 2026.
• Over 3 years, Price to Sales stood at 87.45 in 2024, then declined by 24.67% to 65.88 in 2025, then climbed by 1.71% to 67.0 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 67.0, 192.6, and 65.88 for Q2 2026, Q1 2026, and Q4 2025 respectively.